Surgical Robotics

Surgical robotics is the most commercially mature application of robotic teleoperation and AI-assisted physical manipulation, with over 12 million procedures performed worldwide. The field spans a spectrum from fully teleoperated systems (where a human surgeon controls every movement) to emerging AI-assisted and semi-autonomous capabilities (where the robot handles routine subtasks independently). The market is projected to grow from $7.5–8.5 billion in 2024 to $18–20 billion by 2030.

Intuitive Surgical and da Vinci

Intuitive Surgical dominates surgical robotics with over 8,000 da Vinci units installed globally. The da Vinci 5, unveiled in 2024, represents the most significant platform upgrade in the system's history: 10,000x the computing power of the previous da Vinci Xi, and for the first time, haptic feedback that lets surgeons feel tissue resistance and compliance through the controls. This force feedback is transformative — previous da Vinci generations were purely visual, requiring surgeons to infer tissue properties from visual cues alone.

The da Vinci system is fundamentally a teleoperation platform: the surgeon sits at a console and controls miniaturized instruments inside the patient. The robot provides motion scaling (translating large hand movements into tiny instrument movements), tremor filtering, and access to tight anatomical spaces through small incisions. The surgeon makes every decision; the robot provides precision and access that human hands alone cannot achieve.

The Path to Autonomy

Fully autonomous surgery remains distant, but the steps toward it are visible. Researchers at Johns Hopkins and Stanford integrated a vision-language model with the da Vinci system, training it on 20 hours of surgical video and kinematic data. The resulting system can autonomously perform three critical tasks: lifting body tissue, driving a surgical needle, and suturing a wound. These are narrowly defined tasks in controlled conditions — far from the open-ended decision-making of a full surgical procedure — but they demonstrate that the imitation learning paradigm driving humanoid robots also applies to surgical manipulation.

The likely progression is not a sudden jump to autonomous surgery but a gradual shift in the human-robot division of labor: AI handles routine, repetitive subtasks (suturing a standard pattern, cauterizing along a marked line) while the surgeon focuses on judgment-intensive decisions (identifying anatomy, handling complications, adapting the surgical plan). This shared autonomy model mirrors the trajectory in warehouse robotics and autonomous vehicles — automation of well-defined subtasks first, expanding scope as reliability is proven.

Competitive Landscape

Intuitive's two-decade monopoly in soft-tissue surgical robotics is ending. Medtronic's Hugo and CMR Surgical's Versius Plus received FDA clearance for the U.S. market, introducing the first serious competition. Johnson & Johnson's Ottava is in development. These competitors offer modular designs, lower costs, and in some cases, more advanced AI integration — pressuring Intuitive to accelerate its own AI roadmap. The competitive dynamics may ultimately benefit patients and hospitals by driving down the $1–2 million per-system acquisition costs and accelerating the development of AI-assisted capabilities.

Beyond Soft Tissue

Surgical robotics extends beyond Intuitive's soft-tissue focus. Stryker's Mako dominates orthopedic surgery (knee and hip replacement), using CT-scan-based 3D planning and robotic arm guidance for precise bone cuts. Intuitive's Ion platform handles minimally invasive lung biopsy. Neurosurgical robots enable sub-millimeter precision in brain procedures. Each subspecialty has different requirements for precision, force, imaging integration, and autonomy — creating a diversified market rather than a winner-take-all dynamic.